IN2009CN03372A - - Google Patents

Download PDF

Info

Publication number
IN2009CN03372A
IN2009CN03372A IN3372CHN2009A IN2009CN03372A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A IN 3372CHN2009 A IN3372CHN2009 A IN 3372CHN2009A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A
Authority
IN
India
Prior art keywords
protein
canine
tslp
peptide fragments
canine tslp
Prior art date
Application number
Inventor
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of IN2009CN03372A publication Critical patent/IN2009CN03372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Abstract

Abstract CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological as well as for vaccines that induce anti-TSLP antibodies. The present further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
IN3372CHN2009 2006-12-14 2007-12-11 IN2009CN03372A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
PCT/US2007/025318 WO2008076255A2 (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2009CN03372A true IN2009CN03372A (en) 2015-08-07

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3372CHN2009 IN2009CN03372A (en) 2006-12-14 2007-12-11

Country Status (18)

Country Link
US (3) US7718772B2 (en)
EP (1) EP2104683B1 (en)
JP (4) JP2010512744A (en)
KR (1) KR101525631B1 (en)
CN (2) CN101631800B (en)
AU (1) AU2007334531B2 (en)
BR (1) BRPI0720001A2 (en)
CA (1) CA2671865C (en)
CO (1) CO6210756A2 (en)
ES (1) ES2582655T3 (en)
IL (2) IL199170A (en)
IN (1) IN2009CN03372A (en)
MX (1) MX2009006470A (en)
NZ (1) NZ578352A (en)
RU (2) RU2457217C2 (en)
UA (3) UA95329C2 (en)
WO (1) WO2008076255A2 (en)
ZA (1) ZA200904152B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076255A2 (en) * 2006-12-14 2008-06-26 Schering-Plough Ltd. Canine thymic stromal lymphopoietin protein and uses thereof
JP5492158B2 (en) * 2011-08-24 2014-05-14 富士フイルム株式会社 Antibodies against human TSH and dog TSH
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (en) * 2012-05-04 2014-12-17 Intervet Int Bv PROTEIN OF FUSION OF PROTEIN LINFOPOYETINA ESTROMAL TIMICA CANINA WITH THE REGION FC OF IGG
WO2014162007A2 (en) * 2013-04-04 2014-10-09 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2015020193A1 (en) * 2013-08-09 2015-02-12 アステラス製薬株式会社 Novel anti-human tslp receptor antibody
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
JP6938383B2 (en) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． Antibodies to canine interleukin-4 receptor alpha
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
BR112018003326A2 (en) 2015-09-09 2018-09-18 Novartis Ag thymic stromal lymphopoietin (tslp) binding antibodies and methods of use of antibodies
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3041717A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
CN115028722A (en) * 2021-03-05 2022-09-09 拜西欧斯（北京）生物技术有限公司 anti-TSLP antibody, preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ATE362534T2 (en) 1998-11-13 2007-06-15 Immunex Corp HUMAN TSLP NUCLEIC ACIDS AND POLYPEPTIDES
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc Secreted proteins and uses thereof
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
ATE419351T1 (en) 2000-06-28 2009-01-15 Amgen Inc THYM STROMA LYMPHOPOIETIN RECEPTOR MOLECULES AND THEIR USE
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
ATE407691T1 (en) * 2003-07-18 2008-09-15 Schering Corp TREATMENT AND DIAGNOSIS OF NEOPLASIA WITH TSLP (THYMIC STROMAL LYMPHOPOIETIN)
WO2006023226A2 (en) * 2004-07-28 2006-03-02 Tanox, Inc. Thymic stromal lymphopoietin promoter and uses therefor
SE532251C2 (en) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab New formulations of TSLP for the treatment of TH2-mediated inflammatory diseases by vaccination
WO2008076255A2 (en) 2006-12-14 2008-06-26 Schering-Plough Ltd. Canine thymic stromal lymphopoietin protein and uses thereof

Also Published As

Publication number Publication date
CN101631800B (en) 2012-12-05
MX2009006470A (en) 2009-06-26
JP2012090647A (en) 2012-05-17
CN102584998B (en) 2017-07-04
CA2671865A1 (en) 2008-06-26
EP2104683B1 (en) 2016-05-25
WO2008076255A3 (en) 2008-09-18
UA120027C2 (en) 2019-09-25
US8076456B2 (en) 2011-12-13
UA95329C2 (en) 2011-07-25
NZ578352A (en) 2012-05-25
RU2012113162A (en) 2013-10-20
JP2015107121A (en) 2015-06-11
CO6210756A2 (en) 2010-10-20
RU2009126617A (en) 2011-01-20
JP5707380B2 (en) 2015-04-30
US20130183291A1 (en) 2013-07-18
JP2013048637A (en) 2013-03-14
CA2671865C (en) 2017-01-10
CN102584998A (en) 2012-07-18
BRPI0720001A2 (en) 2013-12-24
IL199170A (en) 2015-04-30
JP6117767B2 (en) 2017-04-19
EP2104683A2 (en) 2009-09-30
RU2617957C2 (en) 2017-04-28
UA108064C2 (en) 2015-03-25
IL215507A0 (en) 2011-11-30
AU2007334531B2 (en) 2012-04-12
US20080152620A1 (en) 2008-06-26
KR20090097921A (en) 2009-09-16
AU2007334531A1 (en) 2008-06-26
KR101525631B1 (en) 2015-06-04
US8791242B2 (en) 2014-07-29
ES2582655T3 (en) 2016-09-14
RU2457217C2 (en) 2012-07-27
JP2010512744A (en) 2010-04-30
US7718772B2 (en) 2010-05-18
CN101631800A (en) 2010-01-20
WO2008076255A2 (en) 2008-06-26
US20110033478A1 (en) 2011-02-10
ZA200904152B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
IN2009CN03372A (en)
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX359903B (en) Mutated parvovirus structural proteins as vaccines.
WO2011032161A8 (en) Vaccines directed to langerhans cells
WO2010104747A3 (en) Antigen presenting cell targeted vaccines
WO2005120565A3 (en) Sars vaccines and methods to produce highly potent antibodies
MY184957A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
WO2007098201A3 (en) Shiga toxoid chimeric proteins
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CU24058B1 (en) PCSK9 ANTAGONISTS
WO2008005880A3 (en) Antibodies for norovirus
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.
WO2008098917A3 (en) Novel antibodies against igf-ir
MX2010001237A (en) Novel antibodies.
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines
ATE519784T1 (en) SUBSTANCE BINDING TO THE HUMAN IGG-FC RECEPTOR IIB (FCGAMMARIIB).
WO2007020520A3 (en) Antigenic peptides and their use
AU2005292852A8 (en) Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
MX2009008754A (en) Novel antibodies against igf-ir.
WO2007127372A3 (en) Genetic adjuvants for viral vaccines
DE602005010680D1 (en) COMPOSITIONS AND METHOD FOR INDUCING AN ANTITUMORIMMUNITY